Diabetes-related metabolic perturbations in cardiac myocyte

Diabetes and Metabolism

Volumn 34, Issue SUPPL. 1, 2008, Pages 3-9

  Feuvray, D ^a   Darmellah, A ^a  

^a CNRS   (France)

Author keywords

Cardiac energy metabolism; Diabetes; Fatty acid utilization; Review; Ventricular dysfunction

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; INSULIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOMYOPATHY; CELL FUNCTION; CELL STRUCTURE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; ENZYME SYNTHESIS; FATTY ACID METABOLISM; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMYOPATHIES; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENERGY METABOLISM; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; REFERENCE VALUES;

EID: 40749126070     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)70096-X     Document Type: Article

References (63)

1. American Diabetes Association, the National Heart, Lung, Blood Institute, the Juvenile Diabetes Foundation International, the National Institute of Diabetes, Digestive, Kidney Disease, the American Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation 100 (1999) 1132-1133
2. Francis G.S. Diabetic cardiomyopathy: fact or fiction?. Heart 85 (2001) 247-248
3. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 30 (1972) 595-602
4. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 34 (1974) 29-34
5. Struthers A.D., and Morris A.D. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359 (2002) 1430-1432
6. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101 (2000) 2271-2276
7. Galderisi M., Anderson K.M., Wilson P.W., and Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy: the Framingham Heart Study. Am J Cardiol. 68 (1991) 85-89
8. Neely J.R., Rovetto M.J., and Oram J.F. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 15 (1972) 289-329
9. Poornima I.G., Parikh P., and Shannon R.P. Diabetic cardiomyopathy. The search for a unifying hypothesis. Circ Res. 98 (2006) 596-605
10. Huss J.M., and Kelly D.P. Nuclear receptor signaling and cardiac energetics. Circ Res. 95 (2004) 568-578
11. Chawla A., Repa J.J., Evans R.M., and Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 294 (2001) 1866-1870
12. Lee C.-H., Olson P., and Evans R.M. Lipid metabolism, metabolic diseases, and peroxisome proliferators-activated receptors. Endocrinology 144 (2003) 2201-2207
13. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator activated receptor α (PPARα). J Biol Chem. 273 (1998) 5678-5684
14. Djouadi F., Brandt J., Weinheimer C.J., Leone T.C., Gonzalez F.J., and Kelly D.P. The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 60 (1999) 339-343
15. Watanabe K., Fujii H., Takahashi T., Kodama M., Aizawa Y., Ohta Y., et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem. 275 (2000) 22293-22299
16. Campbell F.M., Kozak R., Wagner A., Altarejos J.Y., Dyck J.R., Belke D.D., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 277 (2002) 4098-4103
17. Finck B., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 109 (2002) 121-130
18. Christoffersen C., Bollano E., Lindegaard M.L.S., Bartels E.D., Goetze J.P., Andersen C.B., et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144 (2003) 3483-3490
19. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Bætens D., et al. Lipotoxic heart disease in obese rats: implications for human disease. Proc Natl Acad Sci USA 97 (2000) 1784-1789
20. Young M.E., Guthrie P.H., Razeghi P., Leighton B., Abbasi S., Patil S., et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51 (2002) 2587-2595
21. Finck B., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., et al. A critical for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation of phenotype by dietary fat content. Proc Natl Acad Sci USA 100 (2003) 1226-1231
22. Reaven G.M., Hollenbeck C., Jeng C.-Y., Wu M.S., and Chen Y.-D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37 (1988) 1020-1024
23. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258 (1992) 766-770
24. Frayne K.N. Insulin resistance and lipid metabolism. Curr Opin Lipidol. 4 (1993) 197-204
25. Boden G., Chen X., Ruiz J., White J.V., and Rosetti L. Mechanism of fatty acid induced inhibition of glucose uptake. J Clin Invest. 93 (1994) 2438-2446
26. Saltiel A.R., and Pessin J.E. Insulin signalling pathways in time and space. Trends Cell Biol. 12 (2002) 65-71
27. Saltiel A.R., and Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
28. Hue L., Beauloye C., Marsin A.-S., Bertrand L., Horman S., and Rider M.H. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signalling pathways. J Mol Cell Cardiol. 34 (2002) 1091-1097
29. Kim J.K., Fillmore J.J., Sunshine M.J., Albrecht B., Higashimori T., Kim D.W., et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest. 114 (2004) 823-827
30. Feuvray D., Idell-Wenger J.A., and Neely J.R. Effects of ischemia on rat myocardial function and metabolism in diabetes. Circ Res. 44 (1979) 322-329
31. Folmes C.D., Clanachan A.S., and Lopaschuk G.D. Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ Res. 99 (2006) 61-68
32. Hardie D.G., Carling D., and Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?. Annu Rev Biochem. 67 (1998) 821-855
33. Kudo N., Barr A.J., Barr R.L., Desai S., and Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'AMP-activated protein kinase inhibition of acetyl CoA carboxylase. J Biol Chem. 270 (1995) 17513-17520
34. Feuvray D. Diabetic cardiomyopathy. Arch Mal Cœur Vaiss 97 (2004) 261-265
35. Beauloye C., Marsin A.S., Bertrand L., Krause U., Hardie D.G., Vanoverschelde J.L., et al. Insulin antagonizes AMP-activated protein activation by ischemia or anoxia in rat hearts without affecting total adenine nucleotides. FEBS Lett. 505 (2001) 348-352
36. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest. 106 (2000) 171-176
37. Liu G.X., Hanley P.J., Ray J., and Daut J. Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to KATP channels in the heart. Circ Res. 88 (2001) 918-924
38. Peterson L.R., Herrero P., Schechtman K.B., Racette S.B., Waggoner A.D., Kisrieva-Ware Z., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004) 2191-2196
39. Burkhoff D., Weiss R.G., Schulman S.P., Kalil-Filho R., Wannenburg T., and Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am. J. Physiol. 261 (1991) H741-H750
40. Rousset S., Alves-Guerra M.C., Mozo J., Miroux B., Cassard-Doulcier A.M., Bouillaud F., et al. The biology of mitochondrial uncoupling proteins. Diabetes 53 (2004) S130-S135
41. Boss O., Hagen T., and Lowell B.B. Perspectives in diabetes. Uncoupling proteins 2 and 3. Potential regulators of mitochondrial energy metabolism. Diabetes 49 (2000) 143-156
42. Hidaka S., Kakuma T., Yoshimatsu H., Sakino H., Fukuchi S., and Sakata T. Streptozotocin treatment upregulates uncoupling protein 3 expression in the rat heart. Diabetes 48 (1999) 430-435
43. Young M.E., Patil S., Ying J., Depre C., Ahuja H.S., Shipley G.L., et al. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 15 (2001) 833-845
44. Oberkofler H., Neschen S., Esterbauer H., Waldhausl W., Patsch W., and Furnsinn C. UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats. Biochim. Biophys. Acta. 1517 (2000) 113-118
45. Boudina S., Sena S., Theobald H., Sheng X., Wright J.J., Hu X.X., et al. Mitochondrial energetics in the heart in obesity related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56 (2007) 2457-2466
46. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Bætens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97 (2000) 1784-1789
47. Schrauwen P., and Hesselink M.K. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53 (2004) 1412-1417
48. Vincent H.K., Powers S.K., Dirks A.J., and Scarpace P.J. Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord 25 (2001) 378-388
49. Conti M., Renaud I.M., Poirier B., Michel O., Belair M.F., Mandet C., et al. High levels of myocardial antioxidant defense in aging nondiabetic normotensive Zucker obese rats. Am J Physiol, Regul Integr Comp Physiol. 286 (2004) R793-R800
50. Carley A.N., and Severson D.L. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734 (2005) 112-126
51. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 167 (2004) 399-403
52. Wang C.C., Goalstone M.L., and Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53 (2004) 2735-2740
53. Taniyama Y., Ito M., Sato K., Kuester C., Veit K., Tremp G., et al. Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol. 38 (2005) 375-385
54. Feuvray D. The regulation of intracellular pH in the diabetic myocardium. Cardiovasc Res. 34 (1997) 48-54
55. + antiporter (NHE-1), gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J Mol Cell Cardiol. 27 (1995) 729-742
56. + exchange prevents hypertrophy, fibrosis and heart failure in ß1-adrenergic receptor transgenic mice. Circ Res. 90 (2002) 814-819
57. + exchanger contributes to left-ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia 50 (2007) 1335-1344
58. Nahser P.J., Brown R.E., Okarsson H., Winniford M.D., and Rossen J.D. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91 (1995) 635-640
59. Nitenberg A., Ledoux S., Valensi P., Sachs R., Attali J.-R., and Antony I. Impairment of coronary microvascular dilation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 50 (2001) 1181-1185
60. Szczepaniak L.S., Dobbins R.L., Metzger G.J., Sartoni-D'Ambrosia G., Arbique D., Vongpatanasin W., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 49 (2003) 417-423
61. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18 (2004) 1692-1700
62. Tardiff J.C., Hewett T.E., Factor S.M., Vikstrom K.L., Robbins J., and Leinwand L.A. Expression of the beta (slow) -isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol. 278 (2000) H412-H419
63. Scheuermann-Freestone M., Madsen P.L., Manners D., Blamire A.M., Buckingham R.E., Styles P., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type diabetes. Circulation 107 (2003) 3040-3046